Propagermanium

DRUG2 trials

Sponsors

Dimerix Bioscience Pty Ltd

Conditions

Diabetic Kidney DiseaseFocal Segmental Glomerulosclerosis

Phase 2

Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

CompletedNCT03627715

Dimerix Bioscience Pty LtdDiabetic Kidney Disease

Start: 2018-11-06End: 2020-08-18Updated: 2022-07-29

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

CompletedNCT03649152

Dimerix Bioscience Pty LtdFocal Segmental Glomerulosclerosis

Start: 2018-11-08End: 2020-07-13Updated: 2022-07-29

Related Papers

#296 A mid-study update on the ACTION3 pivotal Phase 3 trial assessing DMX-200 in patients with focal segmental glomerulosclerosis (FSGS)

Nephrology Dialysis Transplantation2025-10-01

#2961 DMX-200 does not induce a haemodynamic effect or an acute change in GFR and has a strong cardiovascular safety profile

Nephrology Dialysis Transplantation2025-10-01

#2953 DMX-200 is effective in reducing urine monocyte chemoattractant protein 1 (MCP-1) levels in patients with FSGS without affecting plasma MCP-1 concentration

Nephrology Dialysis Transplantation2025-10-01

#1166 ACTION3 pivotal Phase 3 & open-label extension study assessing DMX-200 in adult & paediatric patients with focal segmental glomerulosclerosis (FSGS)

Nephrology Dialysis Transplantation2024-05-01